<p>本新闻稿仅供在加拿大发布，不得向美国新闻通讯社分发或在美国传播。</p>
<p>多伦多，2026 年 4 月 27 日（GLOBE NEWSWIRE）——Quantum BioPharma Ltd. FRA:0K91（“<strong>Quantum BioPharma</strong>”），一家致力于建立创新资产和生物技术解决方案组合的生物制药公司，欣然宣布以下公司更新。</p>
<p>Quantum Biopharma 已与 Senergy Communications Capital Inc.（“<strong>Senergy</strong>”）签订为期一个月的合同，合同可续签，自 2026 年 5 月 18 日起生效，提供市场营销和投资者意识服务。Senergy 是一家位于加拿大不列颠哥伦比亚省温哥华的独立市场营销、广告和股东关系公司。Senergy 将设计并执行包括企业品牌、社交媒体和广告活动在内的营销活动。根据协议条款，公司将支付 Senergy 150,000 美元，其中包括 25,000 美元的服务费和 125,000 美元的广告费用。</p>
<p>据公司所知，Senergy 不持有 Quantum Biopharma 的任何股份、期权或认股权证。</p>
<p>Senergy Communications Capital Inc</p>
<p>联系人：Aleem Fidai</p>
<p>地址：1122 Mainland Street #228, Vancouver, BC V6B 5L1</p>
<p>电子邮件：aleem@senergy.capital</p>
<p>网站：www.senergy.capital</p>
<p>电话：（778）772-6740</p>
<p>Quantum Biopharma Ltd.已与 King Tide Media LLC（“<strong>KTM</strong>”）签订为期一个月的合同，合同可续签，自 2026 年 5 月 1 日起生效，提供市场意识服务并促进与股东及其他市场参与者的持续对话。KTM 是一家位于佛罗里达州 Lake Worth 的独立市场营销、广告和股东关系公司。KTM 将设计并执行包括企业品牌、社交媒体和广告活动在内的营销活动。根据协议条款，公司将支付 KTM 125,000 美元。</p>
<p>据公司所知，KTM 不持有 Quantum Biopharma 的任何股份、期权或认股权证。</p>
<p>King Tide Media LLC</p>
<p>地址：806E Windward Way #616, Lantana, Florida, 33462</p>
<p>电子邮件：james@kingtidemedia.net</p>
<p>网站：https://kingtidemedia.net/</p>
<p>电话：（843）368-7691</p>
<p><strong>关于 Quantum BioPharma Ltd.</strong></p>
<p>Quantum BioPharma 是一家致力于建立创新资产和生物技术解决方案组合的生物制药公司，专注于治疗具有挑战性的神经退行性疾病、代谢疾病和酒精滥用障碍，拥有不同开发阶段的药物候选物。通过其全资子公司 Lucid Psycheceuticals Inc.（“<strong>Lucid</strong>”），Quantum BioPharma 专注于其主要化合物 Lucid-MS 的研究和开发。Lucid-MS 是一种专利的新化学实体，已在临床前模型中显示出防止和逆转髓鞘降解的效果，这是多发性硬化症的根本机制。Quantum BioPharma 发明了 unbuzzd 并将其 OTC 版本剥离给一家由行业资深人士领导的公司 Unbuzzd Wellness Inc.（“<strong>UWI</strong>”）。Quantum BioPharma 保留 UWI 19.84% 的股份（截至 2025 年 12 月 31 日），网址为 www.unbuzzd.com。与 UWI 的协议还包括 unbuzzd™销售额的 7% 的特许权使用费，直到支付给 Quantum BioPharma 的总额达到 2.5 亿美元。一旦达到 2.5 亿美元，特许权使用费将永久降至 3%。Quantum BioPharma 保留开发类似产品或替代配方用于制药和医疗用途的 100% 权利。</p>
<p><strong>前瞻性信息</strong></p>
<p><em>本新闻稿包含 “前瞻性声明” 或 “前瞻性信息”（统称 “前瞻性声明”），符合适用证券立法的定义。所有声明，除了历史事实声明外，均为前瞻性声明，基于截至本新闻稿日期的预期、估计和预测。前瞻性声明包括但不限于关于：预计完成发行的时间和预期使用收益的声明。</em></p>
<p><em>前瞻性声明受到各种已知和未知的风险、不确定性和其他因素的影响，这些因素可能导致实际事件或结果与前瞻性声明中所表达或暗示的有所不同。不能保证这些声明将被证明是准确的，因为实际结果和未来事件可能与这些声明中预期的有实质性差异。某些重要因素可能导致实际结果、表现或成就与前瞻性声明中的内容有实质性差异，这些因素在公司的管理讨论与分析中的 “风险与不确定性” 部分中进行了强调。</em></p>
<p><em>前瞻性声明基于一系列估计和假设，尽管公司在此时认为这些估计和假设是合理的，但本质上受到重大商业、经济和竞争的不确定性和意外事件的影响，这可能导致公司的实际财务结果、业绩或成就与此处所表达或暗示的内容有重大差异。用于制定前瞻性声明的一些重要因素或假设包括但不限于：未能完成发行；依赖关键管理人员和其他人员；经济状况可能的下滑；来自其他公司的竞争；市场因素，包括公司开发的未来产品的需求；外国政府的政策和行动，这可能影响公司成功营销其产品的能力；公司在目标收购系统开发方面的预期；目标收购系统的有效性；国家和地方政府立法、税收、管制或法规的变化及/或行政或法律、政策和实践的变化；一般商业和经济状况的影响；货币汇率；以及通货膨胀的影响。</em></p>
<p><em>本新闻稿中包含的前瞻性声明明确受到此警示声明的限制。任何前瞻性声明及其相关假设均为本新闻稿发布日期的内容，因此在该日期之后可能会发生变化。公司不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非适用的证券法律要求。不能保证前瞻性声明将被证明是准确的，因为实际结果和未来事件可能与这些声明中预期的内容有重大差异。因此，读者不应对前瞻性声明过度依赖。</em></p>
<p><strong>联系方式：</strong></p>
<p>Quantum BioPharma Ltd.</p>
<p>Zeeshan Saeed，创始人、首席执行官及董事会执行联合主席</p>
<p>电子邮件：Zsaeed@quantumbiopharma.com</p>
<p>电话：（833）571-1811</p>
<p>投资者关系</p>
<p>电子邮件：ir@quantumbiopharma.com, info@quantumbiopharma.com</p>
<p>网站：www.quantumbiopharma.com</p>

QNTM

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

<p>Quantum BioPharma Ltd. 宣布了公司更新，包括与 Senergy Communications Capital Inc. 和 King Tide Media LLC 签订的市场营销和投资者意识服务合同。Senergy 将获得 150,000 美元，而 KTM 将获得 125,000 美元。该公司专注于开发针对神经退行性疾病和代谢性疾病的创新生物制药解决方案。Quantum BioPharma 持有 Unbuzzd Wellness Inc. 19.84% 的股份，并与其产品 unbuzzd 的销售签订了特许权使用费协议。声明中包含前瞻性陈述，强调潜在的风险和不确定性</p>

<p>THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.</p>
<div class="lb-trans"><p>本新闻稿仅供在加拿大发布，不得向美国新闻通讯社分发或在美国传播。</p>
</div><p>TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. FRA:0K91 (“ <strong>Quantum BioPharma</strong>”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.</p>
<div class="lb-trans"><p>多伦多，2026 年 4 月 27 日（GLOBE NEWSWIRE）——Quantum BioPharma Ltd. FRA:0K91（“<strong>Quantum BioPharma</strong>”），一家致力于建立创新资产和生物技术解决方案组合的生物制药公司，欣然宣布以下公司更新。</p>
</div><p>Quantum Biopharma has retained the services of Senergy Communications Capital Inc. (&#34; <strong>Senergy</strong>&#34;) on a one-month contract with option for renewal, starting May 18, 2026, to provide marketing and investor awareness services. Senergy is an arm's-length marketing, advertising and shareholder relations firm based in Vancouver, B.C. Senergy will design and execute campaigns that include corporate branding, social media, and advertising initiatives. Under the terms of the agreement, the company will pay Senergy USD $150,000 that includes a service fee of USD $25,000 and advertising expenses of USD $125,000.</p>
<div class="lb-trans"><p>Quantum Biopharma 已与 Senergy Communications Capital Inc.（“<strong>Senergy</strong>”）签订为期一个月的合同，合同可续签，自 2026 年 5 月 18 日起生效，提供市场营销和投资者意识服务。Senergy 是一家位于加拿大不列颠哥伦比亚省温哥华的独立市场营销、广告和股东关系公司。Senergy 将设计并执行包括企业品牌、社交媒体和广告活动在内的营销活动。根据协议条款，公司将支付 Senergy 150,000 美元，其中包括 25,000 美元的服务费和 125,000 美元的广告费用。</p>
</div><p>To the Company's knowledge, Senergy does not own any shares, options or warrants in Quantum Biopharma.</p>
<div class="lb-trans"><p>据公司所知，Senergy 不持有 Quantum Biopharma 的任何股份、期权或认股权证。</p>
</div><p>Senergy Communications Capital Inc</p>
<div class="lb-trans"><p>Senergy Communications Capital Inc</p>
</div><p>Contact:Aleem Fidai</p>
<div class="lb-trans"><p>联系人：Aleem Fidai</p>
</div><p>Address:1122 Mainland Street #228, Vancouver, BC V6B 5L1</p>
<div class="lb-trans"><p>地址：1122 Mainland Street #228, Vancouver, BC V6B 5L1</p>
</div><p>Email: aleem@senergy.capital</p>
<div class="lb-trans"><p>电子邮件：aleem@senergy.capital</p>
</div><p>Website: www.senergy.capital</p>
<div class="lb-trans"><p>网站：www.senergy.capital</p>
</div><p>Phone: (778) 772-6740</p>
<div class="lb-trans"><p>电话：（778）772-6740</p>
</div><p>Quantum Biopharma Ltd. has retained the services of King Tide Media LLC (“ <strong>KTM</strong>”) on a one-month contract with option for renewal, starting May 1, 2026, to provide market awareness and foster productive, continuing dialogues with shareholders and other market participants. KTM is an arm’s-length marketing, advertising and shareholder relations firm based in Lake Worth, Florida. KTM will design and execute campaigns that include corporate branding, social media, and advertising initiatives. Under the terms of the agreement, the company will pay KTM USD $125,000.</p>
<div class="lb-trans"><p>Quantum Biopharma Ltd.已与 King Tide Media LLC（“<strong>KTM</strong>”）签订为期一个月的合同，合同可续签，自 2026 年 5 月 1 日起生效，提供市场意识服务并促进与股东及其他市场参与者的持续对话。KTM 是一家位于佛罗里达州 Lake Worth 的独立市场营销、广告和股东关系公司。KTM 将设计并执行包括企业品牌、社交媒体和广告活动在内的营销活动。根据协议条款，公司将支付 KTM 125,000 美元。</p>
</div><p>To the Company's knowledge, KTM does not own any shares, options or warrants in Quantum Biopharma.</p>
<div class="lb-trans"><p>据公司所知，KTM 不持有 Quantum Biopharma 的任何股份、期权或认股权证。</p>
</div><p>King Tide Media LLC</p>
<div class="lb-trans"><p>King Tide Media LLC</p>
</div><p>Address:806E Windward Way #616, Lantana, Florida, 33462</p>
<div class="lb-trans"><p>地址：806E Windward Way #616, Lantana, Florida, 33462</p>
</div><p>Email: james@kingtidemedia.net</p>
<div class="lb-trans"><p>电子邮件：james@kingtidemedia.net</p>
</div><p>Website: https://kingtidemedia.net/</p>
<div class="lb-trans"><p>网站：https://kingtidemedia.net/</p>
</div><p>Phone: (843) 368-7691</p>
<div class="lb-trans"><p>电话：（843）368-7691</p>
</div><p><strong>About Quantum BioPharma Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 Quantum BioPharma Ltd.</strong></p>
</div><p>Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ <strong>Lucid</strong>”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“ <strong>UWI</strong>”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of December 31, 2025) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd ™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.</p>
<div class="lb-trans"><p>Quantum BioPharma 是一家致力于建立创新资产和生物技术解决方案组合的生物制药公司，专注于治疗具有挑战性的神经退行性疾病、代谢疾病和酒精滥用障碍，拥有不同开发阶段的药物候选物。通过其全资子公司 Lucid Psycheceuticals Inc.（“<strong>Lucid</strong>”），Quantum BioPharma 专注于其主要化合物 Lucid-MS 的研究和开发。Lucid-MS 是一种专利的新化学实体，已在临床前模型中显示出防止和逆转髓鞘降解的效果，这是多发性硬化症的根本机制。Quantum BioPharma 发明了 unbuzzd 并将其 OTC 版本剥离给一家由行业资深人士领导的公司 Unbuzzd Wellness Inc.（“<strong>UWI</strong>”）。Quantum BioPharma 保留 UWI 19.84% 的股份（截至 2025 年 12 月 31 日），网址为 www.unbuzzd.com。与 UWI 的协议还包括 unbuzzd™销售额的 7% 的特许权使用费，直到支付给 Quantum BioPharma 的总额达到 2.5 亿美元。一旦达到 2.5 亿美元，特许权使用费将永久降至 3%。Quantum BioPharma 保留开发类似产品或替代配方用于制药和医疗用途的 100% 权利。</p>
</div><p><strong>Forward-Looking Information</strong></p>
<div class="lb-trans"><p><strong>前瞻性信息</strong></p>
</div><p><em>This news release contains “forward-looking statements” or “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Forward-looking statements include, but are not limited to, statements regarding: the expected timing for completion of the Offering and the intended use of proceeds.</em></p>
<div class="lb-trans"><p><em>本新闻稿包含 “前瞻性声明” 或 “前瞻性信息”（统称 “前瞻性声明”），符合适用证券立法的定义。所有声明，除了历史事实声明外，均为前瞻性声明，基于截至本新闻稿日期的预期、估计和预测。前瞻性声明包括但不限于关于：预计完成发行的时间和预期使用收益的声明。</em></p>
</div><p><em>Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements are highlighted in the “Risks and Uncertainties” in the Company’s management discussion and analysis.</em></p>
<div class="lb-trans"><p><em>前瞻性声明受到各种已知和未知的风险、不确定性和其他因素的影响，这些因素可能导致实际事件或结果与前瞻性声明中所表达或暗示的有所不同。不能保证这些声明将被证明是准确的，因为实际结果和未来事件可能与这些声明中预期的有实质性差异。某些重要因素可能导致实际结果、表现或成就与前瞻性声明中的内容有实质性差异，这些因素在公司的管理讨论与分析中的 “风险与不确定性” 部分中进行了强调。</em></p>
</div><p><em>Forward-looking statements are based upon a number of estimates and assumptions that, while considered reasonable by the Company at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies that may cause the Company’s actual financial results, performance, or achievements to be materially different from those expressed or implied herein. Some of the material factors or assumptions used to develop forward-looking statements include, without limitation: the failure to complete the Offering; reliance on key management and other personnel; potential downturns in economic conditions; competition from others; market factors, including future demand products developed by the Company; the policies and actions of foreign governments, which could impact the ability of the Company to successfully market its products; the Company’s expectations in connection with the development of the Target Acquisition System; the effectiveness of the Target Acquisition System; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration or laws, policies and practices; the impact of general business and economic conditions; currency exchange rates; and the impact of inflation.</em></p>
<div class="lb-trans"><p><em>前瞻性声明基于一系列估计和假设，尽管公司在此时认为这些估计和假设是合理的，但本质上受到重大商业、经济和竞争的不确定性和意外事件的影响，这可能导致公司的实际财务结果、业绩或成就与此处所表达或暗示的内容有重大差异。用于制定前瞻性声明的一些重要因素或假设包括但不限于：未能完成发行；依赖关键管理人员和其他人员；经济状况可能的下滑；来自其他公司的竞争；市场因素，包括公司开发的未来产品的需求；外国政府的政策和行动，这可能影响公司成功营销其产品的能力；公司在目标收购系统开发方面的预期；目标收购系统的有效性；国家和地方政府立法、税收、管制或法规的变化及/或行政或法律、政策和实践的变化；一般商业和经济状况的影响；货币汇率；以及通货膨胀的影响。</em></p>
</div><p><em>The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Any forward-looking statements and the assumptions made with respect thereto are made as of the date of this news release and, accordingly, are subject to change after such date. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.</em></p>
<div class="lb-trans"><p><em>本新闻稿中包含的前瞻性声明明确受到此警示声明的限制。任何前瞻性声明及其相关假设均为本新闻稿发布日期的内容，因此在该日期之后可能会发生变化。公司不承担更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非适用的证券法律要求。不能保证前瞻性声明将被证明是准确的，因为实际结果和未来事件可能与这些声明中预期的内容有重大差异。因此，读者不应对前瞻性声明过度依赖。</em></p>
</div><p><strong>Contacts:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Quantum BioPharma Ltd.</p>
<div class="lb-trans"><p>Quantum BioPharma Ltd.</p>
</div><p>Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board</p>
<div class="lb-trans"><p>Zeeshan Saeed，创始人、首席执行官及董事会执行联合主席</p>
</div><p>Email: Zsaeed@quantumbiopharma.com</p>
<div class="lb-trans"><p>电子邮件：Zsaeed@quantumbiopharma.com</p>
</div><p>Telephone: (833) 571-1811</p>
<div class="lb-trans"><p>电话：（833）571-1811</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>Email: ir@quantumbiopharma.com, info@quantumbiopharma.com</p>
<div class="lb-trans"><p>电子邮件：ir@quantumbiopharma.com, info@quantumbiopharma.com</p>
</div><p>Website: www.quantumbiopharma.com</p>
<div class="lb-trans"><p>网站：www.quantumbiopharma.com</p>
</div>

Quantum BioPharma 发布公司最新动态